Frontiers in Cardiovascular Medicine

MARCH 3, 2024

Background Preeclampsia (PE) is associated with subsequent higher risk of cardiovascular and kidney disease. Serum copeptin, as a proxy for vasopressin, and urinary uromodulin, were associated with PE physiopathology and kidney functional mass respectively.

Blood Pressure 64

Blood Pressure Kidney Disease Hypertension Hospital 64

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

Hypertension Journal

SEPTEMBER 14, 2023

BACKGROUND:Hypertension frequently accompanies chronic kidney disease (CKD) as etiology and sequela. Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. We defined CKD as a sustained estimated glomerular filtration rate value <60 mL/min per 1.73 m2or a urine albumin-to-creatinine ratio ≥30 mg/g.

Kidney Disease 40

Kidney Disease Hypertension Blood Pressure Outcomes 40

Circulation

JANUARY 24, 2024

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Stroke Strokes 81

American College of Cardiology

OCTOBER 3, 2024

Patients with chronic kidney disease (CKD) whose systolic blood pressure (SBP), LDL-C and fasting blood glucose (FBG) were controlled to target levels experienced a similar number of primary outcome events as patients without CKD, according to a new study published in JACC.

Kidney Disease 40

Kidney Disease Blood Pressure Outcomes Article 40

Circulation

NOVEMBER 11, 2024

Introduction:Blood pressure targets for the elderly are still controversial, there is a lack of certainty about the benefit and safety of targeting ≤ 130mmHg systolic blood pressure. of patients had cardiovascular disease, 10.9% chronic kidney disease. diabetes, and 15.5% and I2 = 0%, p = 0.44).

Blood Pressure 40

Blood Pressure Hypertension Kidney Disease Outcomes 40

Circulation

NOVEMBER 11, 2024

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among

Diabetes 40

Diabetes Blood Pressure Myocardial Infarction Kidney Disease 40

Journal of the American Heart Association

FEBRUARY 16, 2024

BackgroundClinical outcome of ischemic cardiogenic shock (CS) requiring extracorporeal membrane oxygenation is highly variable, necessitating appropriate assessment of prognosis. Journal of the American Heart Association, Ahead of Print. However, a systemic predictive model estimating the mortality of refractory ischemic CS is lacking.

Cardiogenic Shock 45

Cardiogenic Shock Hospital Myocardial Infarction Kidney Disease 45

Cardiometabolic Health Congress

AUGUST 14, 2024

The focus will be on the intricate interplay between cardiorenal and metabolic conditions, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, driven by lifestyle and health factors. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H.

CME 72

CME Education Diabetes Innovation 72

GEMMS

MAY 22, 2024

Traditional tools like stethoscopes, blood pressure gauges, and electrocardiograms (ECG) are fundamental for standard diagnostic practices. This improves diagnostic accuracy and ultimately leads to better patient outcomes. They also speed up the diagnosis of cardiac diseases, facilitating early detection and care.

Heart Disease 52

Heart Disease Blood Pressure Technology Innovation 52

Stroke Journal

JANUARY 30, 2025

Hypertension, diabetes, hyperlipidemia, and chronic kidney disease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.

Atrial Fibrillation 40

Atrial Fibrillation Hemorrhage Risk Factors Kidney Disease 40

DAIC

DECEMBER 8, 2023

There is clearer focus on risk factor modification—for example, weight loss and obesity prevention, physical activity, smoking cessation, limiting alcohol, and controlling blood pressure and other comorbidities—to help prevent AFib or ameliorate any recurrences or worsening of the disease.

Atrial Fibrillation 52

Atrial Fibrillation AFIB Stroke Strokes 52

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Open Heart

DECEMBER 23, 2024

However, the effects of blood pressure (BP) and changes in BP on bleeding events in patients undergoing percutaneous coronary intervention (PCI) remain poorly understood. This study is aimed to investigate the relationship between systolic BP (SBP) changes during hospitalisation and bleeding events in patients undergoing PCI.

Blood Pressure 40

Blood Pressure Peripheral Arterial Disease Kidney Disease Laboratory 40

DAIC

JANUARY 19, 2024

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure. mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. Kowal, M.D., vs. 14.3%).

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

DAIC

JUNE 28, 2024

milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease.

Kidney Disease 111

Kidney Disease Blood Pressure Cardiovascular Disease Hypertension 111

Journal of the American Heart Association

DECEMBER 18, 2023

BackgroundBoth nighttime systolic blood pressure and pulse rate are associated with adverse outcomes in patients with chronic kidney disease (CKD). However, nighttime double product (DP), which is the product of nighttime systolic blood pressure and pulse rate, has not yet been investigated in this context.

Kidney Disease 40

Kidney Disease Hypertension Blood Pressure Risk Factors 40

DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Physiologically Speaking

DECEMBER 15, 2023

Participating in any resistance training is associated with a 15%–17% lower risk for these outcomes compared to non-participation. Most data suggest that 30–60 minutes per week is sufficient to maximize the risk reduction — benefits start to plateau and then reverse after this threshold.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Physiologically Speaking

DECEMBER 15, 2023

Participating in any resistance training is associated with a 15%–17% lower risk for these outcomes compared to non-participation. Most data suggest that 30–60 minutes per week is sufficient to maximize the risk reduction — benefits start to plateau and then reverse after this threshold.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Cardiometabolic Health Congress

JULY 17, 2024

Join us as we examine the landmark approvals that are revolutionizing patient outcomes. Notes: Approved after initial rejection two years prior based on safety data from Japan, where the drug had been used since 2020 It can only be used in kidney disease patients on dialysis for at least 3 months.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics 59

Cardiometabolic Health Congress

JULY 10, 2024

Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression. His work was particularly influential in understanding racial disparities in disease progression and developing targeted interventions.

Hypertension 52

Hypertension Education Blood Pressure Kidney Disease 52

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 7.4%), death from cardiovascular causes (RR 0.66; 95% CI [0.52, 0.83]; P = 0.0004; 4.0%

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

Stroke Journal

JANUARY 30, 2025

Background and Purpose:Chronic kidney disease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. female, 22.1%

Atherosclerosis 40

Atherosclerosis Kidney Disease Blood Pressure Biomarkers 40

Cardiometabolic Health Congress

JULY 25, 2023

This was a huge gap, because most patients with T2DM die from cardiovascular disease, and until recently, we had no means of preventing adverse cardiovascular events in these patients. Cardiovascular outcomes trials with SGLT-2 inhibitors have shown a strong effect in preventing major cardiovascular events (i.e., Neal, Bruce, et al.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

DAIC

JANUARY 23, 2024

5 Over my career as a cardiovascular surgeon, as well as an immunologist, I have witnessed how current treatments for ASCVD have led to considerable improvements in outcomes, yet many patients remain vulnerable to life-threatening cardiac events.1,6 34 The safety of colchicine, 0.5 μ/L on 0.6

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Cardiometabolic Health Congress

DECEMBER 7, 2023

AF is associated with an increased risk of death as well as multiple adverse outcomes, including stroke, cognitive impairment or dementia, myocardial infarction, sudden cardiac death, heart failure (HF), chronic kidney disease (CKD), and peripheral artery disease (PAD). million.

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Stroke 111

Physiologically Speaking

MAY 3, 2024

1 For the study, male and female rats underwent endurance exercise training for 1, 2, 4, or 8 weeks and had over 18 different tissues harvested 48 hours after their last exercise bout (this was done to prevent the acute influence of exercise on study outcomes). All of the major HSPs were upregulated after exercise.

Exercise 95

Exercise Physiology Research Kidney Disease 95

Cardiometabolic Health Congress

NOVEMBER 14, 2024

With the holiday season approaching and fall in full swing, it’s the perfect time to reaffirm our commitment to delivering excellent care, improving patient outcomes, and making the most of every available resource. cardiometabolic health CME/CE conference: the 19th Annual CMHC. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103